Ligand Pharmaceuticals is developing pradefovir (Phase 2 clinical）

interdetect

Ligand Pharmaceuticals (following its acquisition of Metabasis) is developing pradefovir (remofovir, ICN 2001-3,
MB-06866, Hepavir B), an oral liver-targeting prodrug of adefovir developed using its HepDirect technology, for
the potential treatment of hepatitis B virus (HBV) infection. China licensee Chiva Pharmaceuticals is also investigating the drug for HBV. By November 2010, Ligand had put on hold further development of this phase II program; however in January 2011, following license to Chiva, the program was back in development.

Licensee Valeant Pharmaceuticals (previously Ribapharm), and its sublicensee Schering-Plough, under license
from Metabasis, were previously developing pradefovir. Valeant had initiated phase II trials in the US, Taiwan,
Singapore and Korea in August 2004. By April 2006, these trials were reported to have
been completed [663095]; it had previously reported, in November 2005, that phase III trials were expected
to start in mid-2006. In February 2007, Schering-Plough listed the compound in phase
II development following its acquisition of the drug; however, by May 2007, dosing had
been suspended in a phase II extension study due to carcinogenicity observed in rodent studies.
In July 2007, Metabasis reported that it had regained rights to the drug from previous licensees based on
negative preclinical carcinogenicity data; at that time, phase II studies had been completed and Metabasis
was reviewing all data. In July 2008, Metabasis realigned resources to focus on metabolic
disease candidates. At that time, the company was seeking to outlicense the program; in March 2009,
the company was still seeking a partner to advance the drug into phase III. However, in January 2010,
Ligand acquired Metabasis.



(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

lin12345

配体制药公司（以下其Metabasis收购）正在开发pradefovir（remofovir，仁川2001-3，
的MB - 06866，Hepavir乙），口服肝靶向前体药物阿德福韦其HepDirect开发利用技术，
B型肝炎病毒（HBV）感染的潜在治疗。中国持牌奇瓦制药也正在调查的乙肝病毒药物。 2010年11月，配体上一放，抓住这第二阶段方案的进一步发展，但在2011年1月，继牌照奇瓦，程序又回到了发展。

被许可人非专利药物（以前Ribapharm），其sublicensee先灵葆雅，根据牌照
从Metabasis，以前发展pradefovir。非专利已开始在美国，台湾二期试验
新加坡和韩国在2004年8月。 2006年4月，据报道，这些试验有
已完成[663095];它以前曾报道，在2005年11月，即第三阶段试验，预计
开始于2006年年中。 2007年2月，先灵葆雅在相复上市
II开发的药物后其收购，但2007年5月，加药有
在第二阶段扩展研究发现，由于悬浮在啮齿类动物的致癌性研究。
2007年7月，Metabasis报告说，它已恢复从以前的持牌人的权利基础上的药物
负临床致癌性的数据;在那个时候，第二阶段研究已经完成，Metabasis
正在审查的所有数据。 2008年7月，Metabasis重新调整资源，专注于代谢
疾病的候选人。当时，该公司正在寻求outlicense方案，在2009年3月
该公司仍在寻求合作伙伴，提前进入第三阶段的药物。然而，在2010年1月
配体收购Metabasis。

StephenW

Pradefovir 是 Adefovir的 前体药物(prodrug).

前体药物（prodrug），也称前药、药物前体、前驅藥物等，是指经过生物体内转化后才具有药理作用的化合物。前体药物本身没有生物活性或活性很低，经过体内代谢后变为有活性的物质，这一过程的目的在于增加药物的生物利用度，加强靶向性，降低药物的毒性和副作用。目前前体药物分为两大类：载体前体药物(carrier-prodrug)和生物前体(bioprecursor)。此外农药中也有许多前体药物。
[维基百科，自由的百科全书]

非东亚病夫

妈的~！连临床数据都没有就三期啦~！
贴钱给我都不敢用
而且还是国产的

user321

非东亚病夫 发表于 2011-4-7 11:58
妈的~！连临床数据都没有就三期啦~！
贴钱给我都不敢用
而且还是国产的 ...

我看你就是典型的一个sb式人物，你在哪里看到是国产的了？你是洋鬼子伐？

user321

回复 非东亚病夫 的帖子

你就是中国人里面的“人渣”，认贼做父

user321

非东亚病夫 发表于 2011-4-7 11:58
妈的~！连临床数据都没有就三期啦~！
贴钱给我都不敢用
而且还是国产的 ...

Ligand Pharmaceuticals is located in La Jolla, California on the cliffs just above Torrey Pines Beach. Founded in 1987, Ligand is a biotech company with a rich heritage in drug discovery and development. Ligand has used its drug development expertise to produce over 40 clinical candidates, 22 INDs, and 5 approved drugs. That's a level of productivity that ranks near the top of the biotech industry.
Today, Ligand is operating with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to an efficiently lean corporate cost structure. Ligand's goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, we offer investors a de-risked opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. We believe Ligand has assembled one of the largest and most diversified portfolios of current and future royalty-generating assets in the industry (now over 50 partnered programs). These therapies address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, diabetes, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Bristol-Myers Squibb and AstraZeneca

如果你不认识英文的话叫你主子给你翻译下，无知的人奥。。。。借用你的话“你只是在这里说了在中国不可能谈论的话题”